961 related articles for article (PubMed ID: 15084435)
21. Antinociceptive effects of neurotropin in a rat model of central neuropathic pain: DSP-4 induced noradrenergic lesion.
Kudo T; Kushikata T; Kudo M; Kudo T; Hirota K
Neurosci Lett; 2011 Sep; 503(1):20-2. PubMed ID: 21843596
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
23. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
24. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
Iancu R; Mohapel P; Brundin P; Paul G
Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
[TBL] [Abstract][Full Text] [Related]
25. Noradrenergic modulation of methamphetamine-induced striatal dopamine depletion.
Fornai F; Alessandrì MG; Torracca MT; Bassi L; Scalori V; Corsini GU
Ann N Y Acad Sci; 1998 May; 844():166-77. PubMed ID: 9668674
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Kobayashi K; Takeuchi A; Yano A; Muraoka K; Matsui T; Miyoshi Y; Hamada H; Date I
Eur J Neurosci; 2004 Mar; 19(6):1494-504. PubMed ID: 15066146
[TBL] [Abstract][Full Text] [Related]
27. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
28. Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine.
Moroz IA; Peciña S; Schallert T; Stewart J
Exp Neurol; 2004 Sep; 189(1):78-93. PubMed ID: 15296838
[TBL] [Abstract][Full Text] [Related]
29. Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
Fulceri F; Biagioni F; Ferrucci M; Lazzeri G; Bartalucci A; Galli V; Ruggieri S; Paparelli A; Fornai F
Brain Res; 2007 Mar; 1135(1):219-29. PubMed ID: 17222394
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
31. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
Willis GL; Kelly AM; Kennedy GA
Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
[TBL] [Abstract][Full Text] [Related]
32. GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Petri D; Pum M; Vesper J; Huston JP; Schnitzler A
Behav Brain Res; 2013 Sep; 252():58-67. PubMed ID: 23727148
[TBL] [Abstract][Full Text] [Related]
33. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Wang Y; Wang HS; Wang T; Huang C; Liu J
J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
[TBL] [Abstract][Full Text] [Related]
34. The effect of central cholinergic and noradrenergic denervation on hippocampal sympathetic ingrowth and apoptosis-like reactivity in the rat.
Harrell LE; Parsons DS; Kolasa K
Brain Res; 2005 Feb; 1033(1):68-77. PubMed ID: 15680341
[TBL] [Abstract][Full Text] [Related]
35. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Garcia J; Winkler C; Björklund A; Carta M
Neurobiol Dis; 2012 Sep; 47(3):393-406. PubMed ID: 22579773
[TBL] [Abstract][Full Text] [Related]
36. Additional noradrenergic depletion aggravates forelimb akinesia and abnormal subthalamic nucleus activity in a rat model of Parkinson's disease.
Wang Y; Chen X; Wang T; Sun YN; Han LN; Li LB; Zhang L; Wu ZH; Huang C; Liu J
Life Sci; 2014 Dec; 119(1-2):18-27. PubMed ID: 25445222
[TBL] [Abstract][Full Text] [Related]
37. Olfactory ensheathing cell transplantation restores functional deficits in rat model of Parkinson's disease: a cotransplantation approach with fetal ventral mesencephalic cells.
Agrawal AK; Shukla S; Chaturvedi RK; Seth K; Srivastava N; Ahmad A; Seth PK
Neurobiol Dis; 2004 Aug; 16(3):516-26. PubMed ID: 15262263
[TBL] [Abstract][Full Text] [Related]
38. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
Lane EL; Soulet D; Vercammen L; Cenci MA; Brundin P
Neurobiol Dis; 2008 Nov; 32(2):220-8. PubMed ID: 18675359
[TBL] [Abstract][Full Text] [Related]
39. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Lane EL; Cheetham SC; Jenner P
Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
[TBL] [Abstract][Full Text] [Related]
40. Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease.
Cheng B; Yang X; An L; Gao B; Liu X; Liu S
Brain Res; 2009 Aug; 1286():25-31. PubMed ID: 19559687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
